课题基金 / 基金详情

MUTAGENICITY OF AZT IN CHILDREN OF HIV-INFECTED WOMEN

MUTAGENICITY OF AZT IN CHILDREN OF HIV-INFECTED WOMEN
艾滋病毒感染妇女所生子女的 AZT 致突变性
批准号:
6406804
负责人:
VERNON E WALKER
金额:
$63.28万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-07-11 至 2002-06-30

项目摘要

项目成果

VERNON E WALKER的其他基金

相似基金

相关文献

中文摘要
翻译
齐多夫定(AZT或ZDV)疗法已被证明可降低死亡率 人类免疫缺陷病毒(HIV)的母体传播 在怀孕和分娩期间,但对围产期的长期影响 对婴儿的治疗目前尚不清楚。因为AZT产生了 在几个生物系统中的DNA损伤,并在 啮齿动物的长期跟踪和收益和风险评估 对婴儿的治疗应该包括对基因毒性的评估 ZAT在这些患者中的潜力。在这项研究中,研究人员将 使用一组分子剂量和效应生物标志物来确定 AZT作为胎盘破裂剂或诱变剂的潜能 治疗剂量的孕妇,并产生生物数据 这将改善对AZT长期遗传风险的评估 儿童和成人的治疗。宫内细菌的遗传毒性潜力 AZT治疗将通过对染色体畸变率的评分来评估 (CaS)在淋巴细胞中的表达及体细胞频率的测定 次黄嘌呤-鸟嘌呤磷酸核糖基转移酶的突变(MFS) T细胞(HPRT)基因座和血糖素A(GPA)基因座 新生儿脐带血标本的红细胞:(一) 妊娠和分娩期间使用AZT治疗艾滋病毒感染的妇女 (Ii)未服用AZT的艾滋病毒感染妇女(AZT- 对照组);和(Iii)未感染妇女(对照组), N+50个/组。这些数据将与血浆中的 AZT在脐带血中的浓度及掺入水平 WBC DNA,以及暴露于AZT的啮齿动物T细胞中的 RIA。物质使用的潜在混杂影响 母亲将通过面谈信息、体检等方式进行评估 病史和脐带血血浆中可替宁的筛选。在儿童中 有证据表明AZT在出生时就有遗传毒性, 这些影响将通过测量CA、HPRT和GPA进行评估 产后12个月采集外周血中的MFS。 在这些儿科研究的同时,HPRT检测也将 用于检测暴露在人类淋巴母细胞中的突变(I) 对AZT的体外作用和(Ii)接受AZT剂量范围的小鼠和大鼠的作用 从治疗(对人类)到致癌(对啮齿动物)。终于 分子方法(如Southern杂交和错配扩增 突变分析)将被开发来检测特定的、频繁的 在接受AZT治疗的人类中发现的发生突变(即“热点”) 细胞,然后用来筛选这些特征突变 接触AZT的啮齿动物和儿童。
英文摘要
Zidovudine (AZT or ZDV) therapy has been shown to reduce the rate of maternal transmission of the human immunodeficiency virus (HIV) during pregnancy and delivery, but the long-term effects of perinatal treatment of infants is currently unknown. Because AZT produces DNA damage in several biological systems and is carcinogenic in rodents, long-term follow-up and assessment of the benefits and risks of therapy in infants should include an evaluation of the genotoxic potential of ZAT in these patients. In this study the researchers will use a set of molecular dose and effect biomarkers to determine the potential of AZT to act as a transplacental clastogen or mutagen in pregnant women at therapeutic doses, and to produce biological data that will improve the assessment of the long-term genetic risks of AZT therapy in children and adults. The genotoxic potential of in utero AZT therapy will be valuated by scoring chromosome aberrations (CAS) in lymphocytes and measuring the frequency of somatic mutations (Mfs) at the hypoxanthine-guanine phosphoribosyltransferase (HPRT) locus in T-cells and the glycophorin A (GPA) locus in erythrocytes of cord blood specimens from newborn children of: (I) HIV-infected women treated with AZT during pregnancy and delivery (AZT-treated group); (ii) HIV-infected women not given AZT (AZT- control group); and (iii) uninfected women (control-control group), with n+50/group. These date will be correlated with the plasma concentrations of AZT and the levels of AZT incorporation in cord WBC DNA, and in T-cells from AZT-exposed rodents, quantified by RIA. The potential confounding effects of substance use by the mothers will be assessed by way of interview information, medical histories, and screening for cotinine in cord blood plasma. In children with evidence of AZT-induced genotoxicity at birth, the persistence of these effects will be assessed by measuring CAs and HPRT and GPA Mfs in peripheral blood samples collected 12 months postpartum. Concurrent with these pediatric studies, the HPRT assay will also be used to examine mutations (I) in human lymphoblastoid cells exposed to AZT in vitro and (ii) in mice and rats receiving AZT doses ranging from therapeutic (in Humans) to carcinogenic (in rodents). Finally molecular methods (e.g., Southern blot and mismatch amplification mutation assays) will be developed to detect specific, frequently occurring mutations (i.e., "hotspots") found in AZT-treated human cells and then used to screen for these characteristic mutations in AZT-exposed rodents and children.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
Mutagenicity of the racemic mixtures of butadiene monoepoxide and butadiene diepoxide at the Hprt locus of T-lymphocytes following inhalation exposures of female mice and rats.
雌性小鼠和大鼠吸入暴露后,丁二烯单环氧化物和丁二烯二环氧化物的外消旋混合物在 T 淋巴细胞 Hprt 基因座处的致突变性。
DOI: 10.1016/s0027-5107(99)00105-0
发表时间: 1999
期刊: Mutation research
影响因子: --
作者: [Meng,Q, Henderson,RF, Walker,DM, Bauer,MJ, Reilly,AA, Walker,VE]
通讯作者: Walker,VE
Transplacental mutagenicity of N-ethyl-N-nitrosourea at the hprt locus in T-lymphocytes of exposed B6C3F1 mice.
N-乙基-N-亚硝基脲在暴露的 B6C3F1 小鼠 T 淋巴细胞中 hprt 位点的经胎盘致突变性。
DOI: 10.1002/em.1047
发表时间: 2001
期刊: Environmental and molecular mutagenesis
影响因子: 2.8
作者: [Sussman,HE, Bauer,MJ, Shi,X, Judice,SA, Albertini,RJ, Walker,VE]
通讯作者: Walker,VE
DOI: 10.1002/(sici)1098-2280(1998)32:3
发表时间: 1998-01-01
期刊: ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
影响因子: 2.8
作者: [Meng, QX, Skopek, TR, Walker, VE]
通讯作者: Walker, VE
Plasma and cellular markers of 3'-azido-3'-dideoxythymidine (AZT) metabolism as indicators of DNA damage in cord blood mononuclear cells from infants receiving prepartum NRTIs.
3-叠氮基-3-二脱氧胸苷 (AZT) 代谢的血浆和细胞标记物作为接受产前 NRTI 的婴儿脐带血单核细胞 DNA 损伤的指标。
DOI: 10.1002/em.20298
发表时间: 2007
期刊: Environmental and molecular mutagenesis
影响因子: 2.8
作者: [Meng,Quanxin, Olivero,OfeliaA, Fasco,MichaelJ, Bellisario,Ronald, Kaminsky,Laurence, Pass,KenA, Wade,NancyA, Abrams,ElaineJ, Nesel,CarolJ, Ness,RobertaB, Bigbee,WilliamL, O'Neill,JPatrick, Walker,DaleM, Poirier,MiriamC, Walker,Ve]
通讯作者: Walker,Ve
共 12 条
    Risk for in vivo mutagenesis of the P53 gene by nucleoside analog antiviral drug
    Risk for in vivo mutagenesis of the P53 gene by nucleoside analog antiviral drug
    In utero NRTIs & mtDNA Changes in Cardiac/Vascular Cells
    Mutagenesis of Single/Combined NRTI Drugs in Human Cells
    海外基金